Suppr超能文献

血清甲状腺激素与 3563 名中国成年人慢性肾脏病风险和严重程度的关系。

Association of Serum Thyroid Hormones with the Risk and Severity of Chronic Kidney Disease Among 3563 Chinese Adults.

机构信息

Graduate School, Beijing University of Chinese Medicine, Beijing, China (mainland).

Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China (mainland).

出版信息

Med Sci Monit. 2020 Jun 22;26:e922910. doi: 10.12659/MSM.922910.

Abstract

BACKGROUND Chronic kidney disease (CKD) is a global health problem with an increasing prevalence. We explored the association of serum thyroid hormones with the risk and severity of CKD among Chinese adults. MATERIAL AND METHODS This retrospective study involved 3563 participants. CKD was diagnosed according to the clinical practice guidelines of the 2012 Kidney Disease Improving Global Outcomes guidelines. Effect-size estimates are expressed as odds ratio (OR) and 95% confidence interval (CI). RESULTS Given the strong magnitude of correlation, only 3 thyroid hormones were analyzed: free triiodothyronine (FT3), free thyroxin (FT4), and thyroid-stimulating hormone (TSH). After propensity score matching on age, sex, diabetes, and hypertension, per 0.2 pg/mL increase in FT3 was significantly associated with 35-38% reduced risk of CKD at stage 1-4, and per 0.3 ng/dL increase in FT4 was only significantly associated with 21% reduced risk of CKD at stage 5 (OR, 95% CI: 0.79, 0.69-0.89), and per 0.5 μIU/mL increment in TSH increased the risk of CKD stage 5 by 8% (1.08, 1.02-1.14). Importantly, 3 thyroid hormones acted interactively, particularly for the interaction between FT3 and FT4 in predicting CKD at stage 5 (OR, 95% CI: 1.81, 1.30-2.55 for high FT3-low FT4, 17.72, 7.18-43.74 for low FT3-high FT4, and 22.28, 9.68-51.30 for low FT3-low FT4). CONCLUSIONS Our findings indicate that serum FT3 can be used as an early-stage biomarker for CKD, and FT4 and TSH can be used as advanced-stage biomarkers among Chinese adults.

摘要

背景

慢性肾脏病(CKD)是一个全球性的健康问题,其患病率不断上升。我们探讨了血清甲状腺激素与中国成年人 CKD 风险和严重程度的关系。

材料和方法

本回顾性研究纳入了 3563 名参与者。根据 2012 年肾脏病改善全球结局指南的临床实践指南诊断 CKD。效应大小估计值表示为比值比(OR)和 95%置信区间(CI)。

结果

鉴于相关性很强,仅分析了 3 种甲状腺激素:游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)和促甲状腺激素(TSH)。在按年龄、性别、糖尿病和高血压进行倾向评分匹配后,FT3 每增加 0.2 pg/mL,CKD 1-4 期的风险降低 35-38%,FT4 每增加 0.3ng/dL,CKD 5 期的风险降低 21%(OR,95%CI:0.79,0.69-0.89),TSH 每增加 0.5μIU/mL,CKD 5 期的风险增加 8%(1.08,1.02-1.14)。重要的是,3 种甲状腺激素具有交互作用,尤其是 FT3 和 FT4 之间的交互作用,可预测 CKD 5 期的发生(OR,95%CI:1.81,1.30-2.55 用于高 FT3-低 FT4,17.72,7.18-43.74 用于低 FT3-高 FT4,22.28,9.68-51.30 用于低 FT3-低 FT4)。

结论

我们的研究结果表明,血清 FT3 可作为 CKD 的早期生物标志物,FT4 和 TSH 可作为中国成年人 CKD 晚期的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0808/7331475/54affbeef1dd/medscimonit-26-e922910-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验